A new era for drug discovery is already here: biologics vs small compound drugs

I found a very interesting post in the Biotech-Now blog "Small Companies, Big Returns"  - about the best performing biotech/pharmatech companies according to their revenue in 2012, who's market capitalization have jumped 100 percent. And what triggered me that half of the first 10 companies are working with either biologic or new drug delivery systems for the old or well studied drugs.

Here is the Top 10 of the list

Biologics: Sarepta with unique RNA-based approaches; Interferon alfa-n3 from Hemispherx Biopharma; Affymax with peginesatide, a functional form of erythropoietin); 

New drug delivery systems for for well-known drugs: BioDelivery Sciences with unique patch; Celsion with drug delivery liposomes;

Small compound drugs: Arena Pharmaceuticals with rich GPCR pipeline; topoisomerase II inhibitor of Sunesis and some others compounds; Threshold Pharmaceuticals with DNA alkylator prodrug activated by hypoxic conditions; Repros Therapeutics with steroid small compound drugs.
Mixed pipeline: Adamis Pharmaceuticals.

The next 10 companies show almost identical profile. The final picture looks very interesting and we can definitely say that the drug design and development nowadays evenly distributed between the biologics and small compound drugs. But more interesting that the new drug delivery system can be successfully applied for an old small compound drug reducing side effects and can provide significant benefits for the company.

Table of the top 20 companies according to YTD (Year-to-date) return.

Update: due to some really strange behavior of the Google Chrome I removed direct link to the Biotech-Now blog - it treated as malware, but it's easy to find a blog post in Google.

1 comment:

  1. Definitely it will be useful for many people. So please keep update like this.
    class room pharmacovilance training